A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-03)
This study, called ASPEN-03, is looking at a new treatment approach for advanced head and neck squamous cell carcinoma (HNSCC) that has spread or come back. Patients will receive two medicines: ALX148 and pembrolizumab (also known as Keytruda). Pembrolizumab is already used to treat some cancers. The main goal is to find out how many patients respond to this combined treatment – meaning their tumours shrink or disappear. Researchers will also check how long the treatment works, how safe it is, and what side effects might occur. This is a Phase 2 study, which means it's an earlier-stage trial testing if the new combination is promising.
Auf einen Blick
Worum geht es in dieser Studie?
This study, called ASPEN-03, is investigating a new treatment for a type of cancer known as head and neck squamous cell carcinoma (HNSCC). This particular study focuses on patients whose cancer has either spread (metastatic), cannot be completely removed by surgery (unresectable), or has come back after previous treatment (recurrent).
The trial is looking at a new drug called ALX148 given together with an established cancer medication known as pembrolizumab (you might know it by the brand name Keytruda). Pembrolizumab works by helping your own immune system fight cancer. Researchers want to see if adding ALX148 to pembrolizumab can make the treatment more effective. They are particularly interested in finding out if this combination can shrink tumours or stop them from growing.
This is a 'Phase 2' study, which means it's an important early step in testing new treatments. In this phase, researchers are trying to understand how well the new combination works, how safe it is, and what side effects patients might experience. The information gathered from this study will help determine if this treatment combination should be studied further in larger trials.
Wichtige Erkenntnisse
- This study evaluates a new combination treatment for advanced head and neck cancer.
- It combines a new drug (ALX148) with an existing immunotherapy (pembrolizumab/Keytruda).
- The main aim is to see if the combination shrinks tumours or stops them from growing.
- It's a Phase 2 study, focusing on how well it works and potential side effects.
- Participation involves regular clinic visits, infusions, and monitoring.
Wer könnte berechtigt sein?
To join this study, people must have advanced head and neck squamous cell carcinoma that has either spread to other parts of the body, can't be removed by surgery, or has come back after previous treatment. They must be at least 18 years old.
There will also be other specific medical checks and tests to make sure that taking part in the study is right and safe for you. For example, doctors will review your general health, past treatments, and certain blood test results.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Do I have advanced head and neck squamous cell carcinoma?
- Has my cancer spread, returned after treatment, or is it not removable by surgery?
- Bin ich mindestens 18 Jahre alt?
- Am I generally healthy enough to participate in a clinical trial?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you would receive the study drugs, ALX148 and pembrolizumab, through an intravenous (IV) infusion, meaning it goes directly into your bloodstream. The study team will explain the schedule for these infusions. You will have regular appointments at the clinic for check-ups, blood tests, and scans to see how your body is responding to the treatment and to monitor for any side effects. You'll also be asked about your overall health and any symptoms you might have.
The study will also look at how your body handles the ALX148 drug and whether your body makes antibodies against it. The total time you spend in the study will depend on how your cancer responds to the treatment and generally how you are feeling, but there will be a follow-up period after you stop receiving the study drugs.
Potenzielle Risiken und Vorteile
Standorte (3)
- —UnbestätigtNiederlande
- —UnbestätigtBelgien
- —UnbestätigtSpanien
Häufige Fragen
What is head and neck squamous cell carcinoma?
It's a type of cancer that starts in the flat, thin cells (squamous cells) found in the head and neck area, such as the mouth, throat, or voice box.
What is 'advanced' cancer?
Advanced cancer means the cancer has spread to other parts of the body (metastatic) or has returned after previous treatment and cannot be easily removed by surgery.
What is pembrolizumab (Keytruda)?
Pembrolizumab is a type of immunotherapy that helps your body's immune system fight cancer cells. It's already approved for treating some cancers.
Was ist eine Phase-2-Studie?
Phase 2 studies are early-stage trials that test if a new treatment is effective and safe enough to be studied further in larger groups of people.
Will I know if I'm getting the new drug?
In this study, all participants will receive both ALX148 and pembrolizumab. There isn't a placebo group in this trial.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.